Inventiva (IVA) News Today $2.27 -0.01 (-0.44%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 7:21 PM | finanznachrichten.deINVENTIVA: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25 at 4:00 PM | globenewswire.comInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 19, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces a €20.1 million issuance of royalty certificatesJuly 19, 2024 | globenewswire.comHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxJuly 18, 2024 | globenewswire.comInventiva announces a €20.1 million issuance of royalty certificatesJuly 17, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Sees Large Growth in Short InterestInventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 130,800 shares, an increase of 12.6% from the June 15th total of 116,200 shares. Based on an average daily trading volume, of 15,000 shares, the days-to-cover ratio is currently 8.7 days.July 5, 2024 | globenewswire.comInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial positionJuly 3, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Given Average Recommendation of "Buy" by AnalystsInventiva S.A. (NASDAQ:IVA - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers tJune 30, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Short Interest Up 68.9% in JuneInventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 116,200 shares, a growth of 68.9% from the May 31st total of 68,800 shares. Based on an average trading volume of 19,200 shares, the days-to-cover ratio is presently 6.1 days.June 21, 2024 | globenewswire.comResults of the votes of the Combined Shareholders' General Meeting of June 20, 2024June 8, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Receives Average Recommendation of "Buy" from AnalystsInventiva S.A. (NASDAQ:IVA - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokJune 5, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Stock Price Down 5.1%Inventiva (NASDAQ:IVA) Stock Price Down 5.1%May 30, 2024 | globenewswire.comCombined General Meeting of June 20, 2024 - Availability of the preparatory documentsMay 28, 2024 | seekingalpha.comAltimmune: A Potential Minor Player In The Massive GLP-1 SpaceMay 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces two scientific presentations at the EASL International Liver Congress 2024May 22, 2024 | globenewswire.comInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024May 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports 2024 First Quarter Financial Information and provides a corporate updateMay 21, 2024 | globenewswire.comInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateMay 16, 2024 | globenewswire.comInventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHMay 14, 2024 | finance.yahoo.comFull Video Coverage: Investor Engagement in Private vs. Public Markets Panel From IPO Edge Bootcamp at NasdaqMay 13, 2024 | globenewswire.comInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorApril 28, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Short Interest UpdateInventiva S.A. (NASDAQ:IVA - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 77,700 shares, a growth of 34.9% from the March 31st total of 57,600 shares. Based on an average trading volume of 39,500 shares, the short-interest ratio is currently 2.0 days.April 26, 2024 | wsj.comInventiva S.A. ADRApril 19, 2024 | msn.comHepion ends Phase 2 study for NASH drug due to cash restraintsApril 8, 2024 | marketbeat.comCanaccord Genuity Group Increases Inventiva (NASDAQ:IVA) Price Target to $20.00Canaccord Genuity Group lifted their price objective on shares of Inventiva from $12.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday.April 4, 2024 | marketbeat.comInventiva S.A. Expected to Earn FY2025 Earnings of ($2.92) Per Share (NASDAQ:IVA)Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities researchers at HC Wainwright upped their FY2025 EPS estimates for Inventiva in a research note issued on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will earn ($2.92) per share for the year, up from their preApril 3, 2024 | globenewswire.comInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FApril 3, 2024 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for Inventiva S.A. (NASDAQ:IVA)Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright boosted their FY2028 EPS estimates for Inventiva in a report released on Monday, April 1st. HC Wainwright analyst E. Arce now anticipates that the company will earn $2.45 per share for the year, up from theirApril 1, 2024 | msn.comJulianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical TrialsApril 1, 2024 | finance.yahoo.comInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call TranscriptApril 1, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Inventiva in a research report on Monday.March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)March 28, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces the nomination of Andre Turenne as DirectorMarch 28, 2024 | globenewswire.comInventiva announces the nomination of Andre Turenne as DirectorMarch 27, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports its 2023 full-year resultsMarch 27, 2024 | globenewswire.comInventiva reports its 2023 full-year resultsMarch 22, 2024 | globenewswire.comInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsMarch 21, 2024 | markets.businessinsider.comPromising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH TreatmentMarch 20, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $22.00 price objective on shares of Inventiva in a research note on Wednesday.March 20, 2024 | marketbeat.comInventiva (IVA) to Release Quarterly Earnings on WednesdayInventiva (NASDAQ:IVA) will be releasing earnings after the market closes on Wednesday, March 27, Zacks reports.March 18, 2024 | markets.businessinsider.comPRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA ApprovalMarch 18, 2024 | globenewswire.comInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DMarch 18, 2024 | seekingalpha.comMadrigal: Accelerated Rezdiffra Approval Puts It In The NASH LeadMarch 14, 2024 | bizjournals.comShares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatmentMarch 13, 2024 | globenewswire.comInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DMarch 8, 2024 | markets.businessinsider.comInventiva’s Clinical Progress and Financial Valuation Reinforce Buy RatingMarch 8, 2024 | markets.businessinsider.comInventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising OutlookMarch 7, 2024 | globenewswire.comInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedFebruary 23, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) to Post FY2023 Earnings of ($2.26) Per Share, HC Wainwright ForecastsInventiva S.A. (NASDAQ:IVA - Free Report) - Investment analysts at HC Wainwright upped their FY2023 earnings per share estimates for shares of Inventiva in a research note issued to investors on Tuesday, February 20th. HC Wainwright analyst E. Arce now anticipates that the company will earn ($2.2 Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here IVA Media Mentions By Week IVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.500.62▲Average Medical News Sentiment IVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼31▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRTC News Today CMPS News Today TBPH News Today HRTX News Today OCS News Today ALT News Today RVNC News Today CYRX News Today ESPR News Today KRRO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
